Overview

* CytomX Q3 2025 revenue misses analyst expectations, declining significantly year-over-year

* Net loss for Q3 2025 was $14.2 mln

* Company maintains strong cash position with $143.6 mln in cash and investments

Outlook

* Company plans CX-2051 Phase 1 data update in Q1 2026

* CytomX to start CX-2051 Phase 1b CRC study with bevacizumab in Q1 2026

Result Drivers

* REVENUE DECLINE - Revenue decreased due to completion of Bristol Myers Squibb collaboration obligations and reduced Moderna activities

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Miss $5.96 $11.63

Revenue mln mln (8

Analysts

)

Q3 Net -$14.23

Income mln

Q3 Cash $143.60

& mln

Investme

nts

Q3 $21.73

Operatin mln

g

Expenses

Q3 -$15.77

Operatin mln

g Income

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)